Open Forum Infect Dis . T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children

[tetano]

Open Forum Infect Dis


. 2025 Nov 20;12(12)faf699.
doi: 10.1093/ofid/ofaf699. eCollection 2025 Dec. T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children

Isabel Vogler[SUP] 1 [/SUP], Stephanie Renken[SUP] 1 [/SUP], Rolf Hilker[SUP] 1 [/SUP], Bonny Gaby Lui[SUP] 1 [/SUP], Andrew Finlayson[SUP] 1 [/SUP], Alejandra Gurtman[SUP] 2 [/SUP], Charulata Sabharwal[SUP] 2 [/SUP], Nicholas Kitchin[SUP] 3 [/SUP], Stephen Lockhart[SUP] 3 [/SUP], William C Gruber[SUP] 2 [/SUP], Kathrin U Jansen[SUP] 2 [/SUP], Kena A Swanson[SUP] 2 [/SUP], Özlem Türeci[SUP] 1 4 [/SUP], Uğur Şahin[SUP] 1 4 5 [/SUP]



Affiliations

• PMID: 41356265
• PMCID: PMC12680099
• DOI: 10.1093/ofid/ofaf699

Abstract

Phase 1 and Phase 2/3 trials (NCT04816643) demonstrated that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 is tolerable and efficacious in (5-11-year-olds) following two 10 µg doses 21 days apart, and a third 10 µg dose after 6 months. Here, we show that vaccination induces neutralizing antibodies and T-cell immunogenicity in 10-11-year-old participants.

Keywords: COVID-19; SARS-CoV-2; T-cell responses; children; vaccine.

​